Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-060123
Filing Date
2025-04-29
Accepted
2025-04-29 16:10:04
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A lctx_proxy_2025_-_naa.htm DEFA14A 27929
2 GRAPHIC img37997875_0.jpg GRAPHIC 1241387
3 GRAPHIC img37997875_1.jpg GRAPHIC 80020
  Complete submission text file 0000950170-25-060123.txt   1847442
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-12830 | Film No.: 25887613
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)